Citi tells investors it’s time to sell Moderna after 600%-plus stock gains
Revenue and profit forecasts fail to justify the hype baked into Moderna’s share price, according to Citi’s analysts.
Read Full Article on MarketWatchAI SUMMARY
# Citi Downgrades Moderna After 600% Rally Citi analysts have issued a sell recommendation on Moderna, arguing that the biotech company's revenue and profit forecasts do not support its elevated valuation following the stock's 600%-plus surge. The downgrade suggests that investor enthusiasm for Moderna has outpaced the company's actual financial fundamentals, signaling potential downside risk for current shareholders.
More Top Stories News
‘I’m afraid of human stupidity’: Why this top economist prefers U.S. tech and gold over bonds
Boeing was at risk of losing all fighter-jet production altogether. Now the stock is up on a new Navy contract.
Why Tuesday was one of the most disturbing days for markets in recent memory, according to a Goldman Sachs pro
He’s been badmouthing Treasury bonds since 2020, but now ‘the big fat cushion’ of 5.25% yields is turning this strategist bullish
One group of funds is holding up the stock market. Barclays says oil prices have to fall to drive a year-end rally.
Content sourced from MarketWatch. Not financial advice.